Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity[2].In Vitro: Swainsonine (0-40 μM; 12 h) shows antiproliferative activity in U251 and LN444 cells[2].
Swainsonine (30 μM; 12 h) induces apoptosis and cell cycle arrest at G2/M phase, and decreases the expression of CyclinD1 and CDK4 protein levels, increases the expression of p16 protein level[2].
Swainsonine (30 μM; 12 h) reduces glioma cell migration and invasion[2].In Vivo: Swainsonine (1 mg/kg; i.p.; twice daily for ten days) and cisplatin increases the anti-tumor efficacy in mouse.